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Abstract 37 
 38 
Background 39 
Tumour necrosis factor inhibition (TNFi) and B cell depletion are highly effective 40 
treatments for active rheumatoid arthritis (RA) but to date no randomised controlled trials 41 
have directly compared their safety, efficacy and cost effectiveness. This study was 42 
undertaken to test the hypothesis that using rituximab would be clinically non-inferior and 43 
cheaper compared to TNFi therapy in biologic-naive patients with RA. 44 
  45 
Methods 46 
An open label randomised controlled trial of two strategies of treatment over 12 months 47 
in patients with active, sero-positive RA and an inadequate response to synthetic 48 
disease modifying anti-rheumatic drugs (DMARDs). Patients were randomised (1:1) to 49 
receive either rituximab or TNFi (either etanercept or adalimumab) as their first biologic 50 
DMARD. Patients switched treatment to the alternative mode of action biologic in the 51 
event of drug-related toxicity or lack/loss of response. The primary outcome measure 52 
was the change in 28 joint count disease activity score (DAS28-ESR) between 0 and 12 53 
months. The non-inferiority margin was specified as 0.6 DAS28-ESR units. 54 
 55 
Findings 56 
295 patients were randomised and treated with either rituximab or TNFi therapy. At 57 
baseline, there were no significant differences between the groups in age, gender, 58 
disease duration, disease activity or intolerance to methotrexate. After 12 months, the 59 
change in DAS28-ESR for patients randomised to rituximab-first (-2.7) was non-inferior 60 
to that for patients randomised to TNFi-first (-2.6) with the difference lying within the pre-61 
specified non-inferiority limit of 0.6 units (estimated difference -0.19, 95% CI -0.51, 0.13; 62 
p=0.24). No between-group differences were found for the proportion of patients 63 
achieving good response (rituximab 43% v TNFi 40%), DAS28-ESR remission (rituximab 64 
23% v TNFi 21%), ACR20 (rituximab 66% v TNFi 71%), ACR50 (rituximab 49% v TNFi 65 
45%) or ACR70 (rituximab 25% v TNFi 23%) response. There were no differences in the 66 
change in health assessment questionnaire (HAQ) score, Hospital Anxiety and 67 
Depression (HAD) score or health-related quality of life. A higher proportion of patients 68 
switched from TNFi therapy to rituximab than vice versa (rituximab 19% v TNFi 32.5%, 69 
p=0.008). The health related costs associated with the rituximab-first strategy were lower 70 
than the TNFi-first strategy (£8391 v £10,356 per patient, p<0.001). In summary, starting 71 
treatment with rituximab is non-inferior to initial TNFi therapy in biologic-naïve patients 72 
with sero-positive RA, and is cost saving over 12 months. 73 
 74 
Funding 75 
The study was funded by Arthritis Research UK. Roche provided supplies of rituximab 76 
free of charge. 77 
 78 
Trial Registration 79 
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Background 88 
TNF inhibitor (TNFi) therapy is an integral component of the drug treatment of 89 
rheumatoid arthritis (RA) patients who fail to exhibit or maintain an adequate response to 90 
non-biologic Disease Modifying Anti-Rheumatic Drugs (nbDMARDs).1 Five originator 91 
TNFi drugs (infliximab, etanercept, adalimumab, golimumab and certolizumab) have 92 
been granted marketing authorisation for the treatment of RA. They are effective in 93 
patients who are nbDMARD-naïve, respond inadequately to methotrexate (MTX-IR), or 94 
fail to respond to another TNFi (TNF-IR). Rituximab is an anti-CD20 monoclonal 95 
antibody that depletes a variety of pathophysiologic subsets within the B cell population. 96 
Rituximab is approved for use in TNF-IR patients2-4 but it is also effective in patients who 97 
are nbDMARD-naïve or MTX-IR.5 It is possible that rituximab is more or less effective 98 
than TNFi therapy in biologic-naïve patients but head to head trials have not been 99 
carried out. In placebo controlled studies, the overall response rates to TNFi or rituximab 100 
therapy are similar. However, important differences between the study populations make 101 
indirect comparison of limited usefulness, and the data are compatible with important 102 
clinical differences in safety, efficacy or cost effectiveness. 103 
 104 
All biologics are expensive and the relative cost effectiveness of each therapy needs to 105 
be considered, but there is considerable uncertainty associated with health economic 106 
modelling. For example in the UK, the cost of TNFi therapy is approximately £9-10,000 107 
per annum; rituximab costs ~£3,500 per treatment course, which needs to be repeated 108 
every 6-9 months giving an annual cost of £4700 - 7000. Were rituximab to prove as 109 
effective as TNFi therapy in biologic-naïve patients it could result in substantial 110 
reductions in healthcare costs. On the other hand, if TNFi therapy is more effective than 111 
rituximab therapy, it would be important to have good evidence to inform health 112 
technology appraisals which might otherwise conclude from the available evidence that 113 
rituximab offers a more cost-effective alternative. 114 
 115 
The Optimal Management of RA patients who Require Biologic Therapy (ORBIT) study 116 
was designed to compare the efficacy, safety and cost-effectiveness of rituximab-first 117 
and TNFi-first strategies in biologic-naïve RA patients with active disease despite 118 
nbDMARD therapy. The hypothesis was that a treatment strategy that starts with 119 
rituximab, and switches to TNFi if required, would be non-inferior to a strategy that starts 120 
with TNFi therapy, and switches to rituximab if required. Further, the study sought to 121 
estimate the incremental cost effectiveness ratio (ICER) of the more effective drug (if it is 122 
associated with higher costs) or the total cost savings associated with prescribing the 123 
cheaper drug (if it is at least as effective as the more expensive drug). 124 
 125 
Methods 126 
The study protocol was approved by the West of Scotland Research Ethics Committee 127 
and registered with ClinicalTrials.gov (NCT01021735). All participants provided written, 128 
informed consent. Patients were recruited between 2009 and 2013 from 35 129 
rheumatology departments in the United Kingdom. The study was an open label, 130 
randomised, controlled, non-inferiority trial comparing two strategies of biologic therapy 131 
in biologic naïve patients over 12 months.  132 
 133 
Randomisation and masking 134 
Patients were randomised in a 1:1 ratio to treatment strategy groups using a telephone-135 
operated Interactive Voice Response System. Minimisation was used to ensure similar 136 
numbers of methotrexate intolerant patients were allocated to each group. All patients, 137 
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treating clinicians and research nurse were aware of treatment allocation. Analyses were 138 
conducted by statisticians who were masked to treatment allocation. 139 
 140 
Inclusion/exclusion criteria 141 
Adult patients (>18y) who fulfilled the 1987 ACR classification criteria for a diagnosis of 142 
RA were eligible for the study if they: 1. had active disease (DAS28-ESR>5.1) despite 143 
treatment with at least two nbDMARDs including methotrexate; 2. had not previously 144 
been treated with biologic therapy and; 3. were sero-positive for rheumatoid factor 145 
and/or anti-CCP antibodies. Patients were excluded if they: were pregnant or breast-146 
feeding; were women of child-bearing potential (or men whose partners were women of 147 
child-bearing potential) who were unwilling to use effective contraception; had a history 148 
of another autoimmune rheumatic disease other than RA; had received recent (≤2 149 
weeks) intra-articular or parenteral corticosteroids; had an active infection; had septic 150 
arthritis within a native joint within the last 12 months; had septic arthritis of a prosthetic 151 
joint within 12 months or indefinitely if the joint remained in situ; known HIV or hepatitis 152 
B/C infection; had latent TB infection unless they had completed adequate antibiotic 153 
prophylaxis; had malignancy (other than basal cell carcinoma) within the last 10 years; 154 
had New York Heart Association (NYHA) grade 3 or 4 congestive cardiac failure; had 155 
demyelinating disease; or had any other contra-indication to the study medications as 156 
detailed in their summaries of product characteristics. 157 
 158
Treatment 159 
In the rituximab-first group, patients commenced rituximab, followed by TNFi therapy if 160 
rituximab was stopped because of inefficacy or toxicity. The TNFi-first group used the 161 
reverse sequence, starting with TNFi therapy before rituximab. Lack (or loss) of 162 
response was defined by a failure to achieve (or maintain) an improvement in disease 163 
activity score (DAS28-ESR) of >1.2 from baseline. However, at all times during the 164 
course of the study, the final decision about treatment resided with the patient and 165 
physician. Thus, the study aimed to capture the variety of real life treatment pathways 166 
that patients might follow, measuring the outcomes and relating these back to the 167 
original (randomised) treatment strategy. 168 
 169 
Patients randomised to the rituximab-first group were given rituximab 1g by IV infusion 170 
on days 1 and 15. Pre-medication with oral paracetamol 1g, chlorpheniramine 10mg IV 171 
and methylprednisolone 100mg IV was given 30 minutes before each rituximab infusion. 172 
Patients who responded to rituximab were re-treated with rituximab after 26 weeks if 173 
there was still persistent disease activity (DAS28-ESR>3.2). Patients who flared, with a 174 
rise in DAS28-ESR>1.2 from the lowest DAS28-ESR recorded, could receive early re-175 
treatment but no sooner than 20 weeks after the previous infusion. Patients randomised 176 
to the TNFi-first group were prescribed adalimumab (40mg every other week, sc) or 177 
etanercept (50mg/week, sc) according to the patient’s and rheumatologist’s choice.  178 
 179 
Patients’ disease activity was assessed every month for one year. Response was 180 
defined as an improvement in DAS28-ESR>1.2; good response when the DAS28-ESR 181 
fell to <3.2; and remission when the DAS28-ESR fell to <2.6. Patients could be switched 182 
to the alternative treatment after 12 weeks (or at any visit thereafter) if response was not 183 
achieved or maintained. Patients could switch therapy if drug-related adverse events 184 
occurred. Patients could be treated with non-steroidal anti-inflammatory drugs, 185 
analgesics and nbDMARDs. Changes in concomitant medication and their doses were 186 
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allowed and were recorded. Oral corticosteroids could be prescribed at a dose not 187 
exceeding prednisolone 10mg/day (or equivalent), but the dose had to remain stable 188 
throughout the trial. Intra-articular and intra-muscular triamcinolone could be used, but 189 
not within four weeks of the 6 and 12 month assessments, and all injection(s) were 190 
recorded.  191 
 192 
Outcome measures 193 
Demographic data were collected at baseline; disease activity (DAS28-ESR and CRP) 194 
was assessed every month; and physical function (HAQ score), mood (HAD score) and 195 
health related quality of life (EQ-5D) were recorded every three months. Patients were 196 
asked to complete a diary to capture health care costs and employment data during a 197 
one month period every 6 months. The primary outcome measure was the change in 198 
DAS28-ESR between baseline and 12 months. Secondary outcome measures included: 199 
DAS28-ESR remission, good response, moderate response and non-response; 200 
ACR20/50/70 response; area under the curve of DAS28-ESR between baseline and 12 201 
months; change in HAQ score; change in HAD score; change in EQ-5D; toxicity; and 202 
incremental cost effectiveness. 203 
 204 
Sample size and power calculations 205 
The study was powered to demonstrate non-inferiority of a rituximab-first strategy 206 
compared to TNFi-first strategy in the change from baseline DAS28 score after 12 207 
months of treatment. If the true treatment effect difference is zero, and assuming a 208 
standard deviation of 1.6 units for the change in DAS28 after 12 months,4 then 151 209 
patients per group had 90% power to demonstrate non-inferiority between the study 210 
groups within a one-sided non-inferiority limit of 0.6 units which equates to the 211 
measurement error of DAS28-ESR.6  212 
 213 
Statistical Analysis 214 
The analysis of the primary outcome was carried out on the ‘per protocol’ population7 215 
and tested the null hypothesis that a rituximab-first strategy is inferior to a TNFi-first 216 
strategy, after adjustment for baseline DAS28-ESR using a linear regression model. 217 
Residuals were examined through residual plots and were found to be near-normal 218 
without any evidence of heteroscedasticity. The null hypothesis would be rejected if the 219 
upper limit of the 95% confidence interval in the difference in the mean change in 220 
DAS28-ESR (comparing rituximab-first to TNFi-first) was less than 0.6 units. If rituximab-221 
first was found to be non-inferior to TNFi-first then the p-value and CI will be used in 222 
combination to assess whether rituximab-first is superior to TNFi-first therapy. 223 
Quantitative secondary outcomes were analysed in the intention to treat (ITT) population 224 
which was defined as those patients who were randomised and treated with at least one 225 
dose of study medication. For binary secondary outcomes the odds ratios of response 226 
were estimated from a baseline-adjusted logistic regression models. Adverse events 227 
were also analysed in patients who received at least one dose of study medication. No 228 
interim analyses were planned or undertaken. An independent data monitoring 229 
committee periodically reviewed the occurrence of all serious adverse events. 230 
 231 
Health Economic Analysis 232 
The economic analysis estimated the mean between-group difference in costs and 233 
quality-adjusted life years (QALYs) gained over 12 months. Costs were measured from 234 
the perspective of the health service, and the items of resource use collected included 235 
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costs of medicines, administering infusion, clinic visits, blood tests, radiology tests, 236 
endoscopy, other medicines used, and use of primary care and community services. 237 
Appropriate UK costs were applied using 2014 prices (Supplementary Table). QALYs 238 
were estimated from the area under the health utility curve, derived from EQ-5D 239 
questionnaire responses; the EQ5D was valued using UK time trade-off tariff values. 240 
Since all cost and QALY differences were estimated over the 12 month period from 241 
randomisation, discounting future costs and effects for societal time preference was not 242 
relevant. 243 
 244 
Bootstrapping (5000 samples) and the method of recycled predictions were used to 245 
jointly estimate the mean between-group differences in QALYs and costs with 95% 246 
confidence intervals; these quantities are summarised and presented graphically in the 247 
incremental cost effectiveness plane. 248 
 249 
Role of the funding source 250 
The funders of the study played no part in study design, data collection, data analysis, 251 
data interpretation, writing the manuscript or the decision to submit the manuscript for 252 
publication. 253 
 254 
Results 255 
Three hundred forty four patients were screened for inclusion in the study, and 329 were 256 
randomised. 34 randomised patients (n= 21 to rituximab, and 13 to TNFi) did not receive 257 
any study medication because of inter-current illness or withdrawal of consent. The 258 
intention to treat population comprised 295 patients (144 rituximab-first, and 151 TNFi-259 
first). 135 (94%) in the rituximab-first and 136 (90%) in the TNFi-first groups completed 260 
the follow-up period and were included in the per-protocol analysis of the primary 261 
outcome (Figure 1). In the TNFi-first group, 91 patients were treated with adalimumab 262 
and 60 were treated with etanercept. Baseline demographic characteristics and 263 
measures of disease activity were similar in the treatment groups (Table 1). 264 
 265 
Disease Activity Outcomes 266 
 267 
The per-protocol analysis demonstrated that the rituximab-first treatment strategy was 268 
non-inferior to the TNFi-first strategy, within the pre-specified non-inferiority limit of 0.6 269 
units. The baseline-adjusted between-group difference in the change in DAS28-ESR 270 
between baseline and 12 months follow-up (Figure 2) was estimated as -0.19 (95% CI -271 
0.51, 0.13), p=0.24. The upper confidence limit was less than the pre-specified inferiority 272 
margin, allowing rejection of the null hypothesis that the rituximab-first strategy is inferior 273 
to a TNFi-first strategy. No significant between group differences in DAS28-ESR were 274 
observed at any time point, and there was no difference in the area-under-the-curve 275 
(AUC) for the improvement in DAS28-ESR over 12 months (Supplementary Figure 3, 276 
mean difference in AUC= 64 units (95% CI -20, 147), p=0.13). 277 
 278 
After 6 and 12 months, there were no significant differences in the proportion of patients 279 
achieving ACR20, ACR50, ACR70, DAS28-ESR remission, good response, moderate 280 
response or non-response (Table 2). The groups showed similar improvements in EQ5D 281 
health utility, EQ5D VAS and the Anxiety and Depression Scores of the HAD Scale after 282 
6 and 12 month’s follow-up. The rituximab-first group demonstrated a greater 283 
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improvement in HAQ over time (mean difference [95% CI] = -0.121 [-0.236, -0.006], 284 
p=0.039. Table 3). 285 
 286 
Treatment  287 
 288 
A significantly higher number of patients in the TNFi-first group switched to treatment 289 
with rituximab than the number of rituximab-first patients who switched to TNFi treatment 290 
(33% vs 19% respectively, p=0.008). In the rituximab-first group, 2 patients switched 291 
treatment due to toxicity and 25 due to inefficacy. In the TNFi-first group, 3 patients 292 
switched due to toxicity and 44 switched due to inefficacy. In the rituximab-first group, 57 293 
patients (39%) received 1 course of treatment, 77 (54%) received 2 courses and 10 (7%) 294 
received 3 courses. Of the 49 patients in the TNFi-first group who were switched to 295 
rituximab, 28 (57%) received 1 course and 21 (43%) received 2 courses.  296 
 297 
In patients who switched treatment for inefficacy, there was no difference in DAS28-ESR 298 
at the point of switching (mean [SD] DAS28-ESR: rituximab-first 5.6 [0.9] v TNFi-first 6.3 299 
[1.0]), and there were similar improvements in DAS28-ESR between the switch and 300 
month 12 visits (mean [SD] change in DAS28-ESR: rituximab-first -1.3 [1.5] vs TNFi-first 301 
-1.6 [1.5], p=0.44). More patients in the TNFi-first group achieved a good response after 302 
switching to rituximab than vice versa but this was not statistically significant (rituximab-303 
first 69% vs TNFi-first 86%, p=0.13), and there was no difference in DAS28-ESR at 12 304 
months in those who had switched (mean [SD]: rituximab-first 4.2 [1.5] vs TNFi-first 4.6 305 
[1.1], p=0.32). 306 
 307 
Adverse Events 308 
 309 
One hundred thirty seven (95%) patients in the rituximab-first group and 143 (95%) 310 
patients in the TNFi-first group reported at least 1 adverse event during the follow-up 311 
period (Supplementary Table 5). In the rituximab-first group a higher number of patients 312 
reported diarrhoea (14% vs 6%, p=0.03) whilst, in the TNFi-first group a higher number 313 
of patients reported injection site reactions (2% vs 11%, p=0.003). There were 37 314 
serious adverse events (SAE) reported in patients currently receiving rituximab (31 315 
randomised to rituximab-first arm, and six following a switch from TNFi therapy); of 316 
these, 15/37 were deemed to be possibly, probably or definitely related to the rituximab. 317 
26 patients experienced serious adverse events whilst receiving TNFi therapy (22 318 
randomised to TNFi-first arm, and four following a switch from rituximab) of which 12/26 319 
were deemed possibly, probably or definitely related to the TNFi therapy (p=0.27 for 320 
SAE occurring on rituximab vs TNFi). One patient in each group died during the study 321 
(rituximab – sepsis related to infected elbow prosthesis; TNFi – myocardial infarction).  322 
 323 
Health Economic Outcomes 324 
 325 
Healthcare-related costs, and Quality-Adjusted Life Years (QALYs) for each randomised 326 
group are shown in Table 4 and Supplementary Figure 4. The total healthcare-related 327 
costs were lower in the rituximab-first group (£9,405 vs 11,523, p<0.001). There was no 328 
difference in the mean AUC for EQ-5D (TNFi mean [SD] 0.519 [0.248] vs rituximab 329 
0.546 [0.212], p=0.235) indicating no difference in QALYs gained. Using generalized 330 
linear regression models, age was a significant determinant of cost and EQ-5D but 331 
gender, baseline DAS28-ESR, and methotrexate tolerance were not independently 332 
associated with either (data not shown). Absenteeism costs were slightly lower in the 333 
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rituximab-first group (£6,296 vs £7,662 TNF). Given the lack of evidence of a QALY 334 
difference between groups, and the clear reduction in healthcare-related costs in the 335 
rituximab-first group, the incremental cost effectiveness ratio between treatment 336 
strategies was not relevant to the analysis, and a rituximab-first strategy can be judged 337 
as the more cost-effective option. 338 
 339 
Discussion 340 
Biologic DMARDs are the mainstay of therapy in moderate to severe RA. Many effective 341 
drugs are available that operate through discrete mechanisms of action. There is robust 342 
evidence for their efficacy in a variety of clinical settings; however, since there have 343 
been very few head-to-head clinical trials, there is a paucity of direct evidence about 344 
their comparative efficacy. The AMPLE study found that abatacept and adalimumab 345 
were similarly efficacious in biologic-naïve RA patients,8 and the ADACTA study showed 346 
superiority of tocilizumab monotherapy compared to adalimumab monotherapy in 347 
biologic-naïve RA patients who were intolerant of methotrexate.9 One study compared 348 
infliximab with etanercept, but was too small to provide reliable information about relative 349 
efficacy.10 The RED-SEA study showed that adalimumab was non-inferior to etanercept 350 
in terms of persistence on therapy over 12 months, but was not powered to detect 351 
differences in efficacy.11 The ORBIT study results are broadly similar to those reported in 352 
placebo-controlled randomized controlled trials of the individual drugs,2, 4-5,12-16 but it is 353 
the first head to head RCT comparing B cell depletion with TNF inhibition in RA, and 354 
convincingly shows that a rituximab-first strategy in biologic-naïve RA is non-inferior to a 355 
TNFi-first strategy. The only notable difference between the strategies was that a higher 356 
proportion of patients continued on initial rituximab therapy, without the need to switch 357 
therapy, when compared to those randomised to TNFi-first therapy (81% persistence on 358 
rituximab v 68% persistence on TNFi, p=0.008). 359 
 360 
Rituximab is only approved for use in patients who have failed TNFi therapy. An 361 
application to extend the license to biologic-naïve patients was rejected by the European 362 
Medicines Agency because of the rare occurrence of progressive multi-focal 363 
encephalopathy (PML). In this study, there were no differences observed in the rate, 364 
severity or relationship to study drug in serious adverse effects during the study period. 365 
This observation does not preclude the possibility of relevant differences in rare, but very 366 
serious, toxicity or differences in toxicity associated with long-term use. There were no 367 
cases of PML or demyelination, but two patients died - one from serious sepsis following 368 
rituximab therapy, and one from myocardial infarction on TNFi therapy. 369 
 370 
The majority of patients in the rituximab-first group (93%) received four or fewer 371 
infusions (i.e. two courses) of rituximab. During the study period, the costs associated 372 
with the rituximab-first strategy were substantially lower than those in the TNFi-first 373 
group (mean annual cost per patient: rituximab-first £8391, TNFi-first £10,356). In the 374 
UK, widespread adoption of a rituximab-first strategy, in preference to TNFi-first therapy, 375 
would currently translate into very substantial budgetary savings for health services with 376 
no measurable loss of efficacy. However, the healthcare-related costs were dominated 377 
by drug acquisition and administration costs, which may vary significantly according to 378 
local procurement agreements. The availability of TNFi biosimilars at lower acquisition 379 
costs, or the use of lower doses of drugs (e.g. rituximab 500mg per infusion17) would 380 
also affect the relative cost effectiveness of the two strategies. There are other options 381 
that are available for biologic-naïve RA patients who require biologic therapy, and it is 382 
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possible that another drug/strategy would be even more cost effective than rituximab. 383 
The AMPLE study found that abatacept and adalimumab are equally efficacious, but as 384 
abatacept is more expensive than TNFi therapy, it is almost certain that a rituximab-first 385 
strategy will be more cost effective than an abatacept-first strategy. Because tocilizumab 386 
monotherapy is more effective than adalimumab therapy in patients who are unable to 387 
tolerate methotrexate, it is possible that tocilizumab is more cost effective than rituximab 388 
in this patient population and this requires further study. The TACIT study compared the 389 
efficacy of combination conventional DMARD therapy with TNFi in patients who met the 390 
British Society for Rheumatology/National Institute for Clinical Excellence (BSR/NICE) 391 
eligibility criteria for the use of TNFi therapy, and found that using combination DMARD 392 
was non-inferior to TNFi therapy, and substantially more cost effective.18 A significant 393 
proportion (~40%) of patients randomised to combination DMARD therapy eventually 394 
required TNFi therapy, and the implication of the ORBIT study is that further savings 395 
could be made if patients who fail to make an adequate response to combination 396 
nbDMARD therapy were then treated with rituximab rather than TNFi therapy. 397 
 398 
Our study has limitations: a wide range of clinical outcome measures were captured, but 399 
no radiographic outcomes were recorded. It is possible that a TNFi-first strategy would 400 
be associated with more or less radiographic joint damage, than a rituximab-first 401 
strategy. Secondly, the study was limited to patients who were sero-positive for 402 
rheumatoid factor and/or anti-cyclic citrullinated protein antibodies. Since response to 403 
rituximab is modestly greater in sero-positive patients19 the results of this study should 404 
only be extrapolated to sero-negative patients with caution. Thirdly, patients who were 405 
intolerant of methotrexate were eligible for the study, even though rituximab is only 406 
approved for use in combination with methotrexate. However, this represents real life 407 
experience, and excluding patients who were intolerant of methotrexate would have 408 
limited the study’s generalizability. Minimisation techniques were employed to ensure 409 
similar numbers of methotrexate-intolerant patients were randomised to each group, so 410 
this is unlikely to have significantly influenced the results. Fourthly, this was an open 411 
label study. Both patients and assessors were aware of the patients’ treatment allocation 412 
and therefore there is a possibility of bias. There is no evidence that such bias existed, 413 
or which treatment arm was favoured if it did. A double-blind study design would have 414 
been more complex and costly, and been dependent on funding from three 415 
pharmaceutical companies, for example to provide matched placebo self-injection pen 416 
devices. The benefits accruing from delivering a true-to-life, investigator-initiated, 417 
charitably-funded RCT (and minimising the involvement of the pharmaceutical industry) 418 
were deemed to be more important and thus were given priority in study design. Fifth, 419 
when a patient had not responded, or lost response, the study team was advised to 420 
consider switching but treatment decisions were at the discretion of the treating 421 
physician in discussion with the patient – it is possible, therefore, that patients were kept 422 
on ineffective therapy but (on the other hand) the study will have captured usual 423 
practice. Disease activity at the point of switching was not significantly different in the 424 
two groups, arguing against any systematic bias in this regard. Finally, the 12 month 425 
follow-up period means that the study is unable to provide a comparative description of 426 
either strategy’s long-term efficacy or safety. RA may affect an individual over several 427 
decades, and from a lifetime perspective, other factors are highly relevant – for example, 428 
the rates of long term drug continuation, the ability of each strategy to influence disease 429 
progression, and any effect on life expectancy. 430 
 431 
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In conclusion, initial therapy with rituximab is clinically non-inferior to and more cost 432 
effective than initial therapy with a TNFi drug in sero-positive RA patients who are 433 
eligible for biologic therapy in the UK.  434 
 435 
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Figure 1 Consort diagram 565 
566 
Assessed for eligibility (n=344) 
Excluded  (n=15) 
♦   Not meeting inclusion criteria (n=4) 
♦   Declined to participate (n=4) 
♦   Other reasons (n=7) 
Per protocol analysis (n=135) 
♦ intention to treat analysis (n=144) 
Lost to follow-up (n=10) 
♦ death (n=1) 
♦ lost to follow up (n=0) 
♦ intercurrent illness (n=1) 
♦ withdrawn consent (n=4) 
♦ SAE (n=2) 
♦ SAR (n=0) 
♦ Non-compliance (n=0) 
♦ Investigator terminated (n=1) 
♦ No reason (n=1) 
 
Allocated to rituximab first (n=165) 
♦ Received rituximab (n=144) 
♦ Did not receive rituximab (n=21) 
- Intercurrent illness n=3 
- Ineligible n=1 
- DAS28<5.1 n=2 
- Consent withdrawn n=13 
- Other n=2 
Lost to follow-up (n=16) 
♦ death (n=1) 
♦ lost to follow up (n=4) 
♦ intercurrent illness (n=2) 
♦ withdrawn consent (n=4) 
♦ SAE (n=1) 
♦ SAR (n=1) 
♦ Non-compliance (n=1) 
♦ Investigator terminated (n=2) 
 
 
Allocated to TNFi first (n=164) 
♦ Received TNFi (n=151) 
♦ Did not receive TNFi (n=13) 
- Intercurrent illness n=3 
- Ineligible n=2 
- Required oral steroids n=1 
- DAS28<5.1 n=1 
- Decision by PI n=1 
- Consent withdrawn n=4 
- Other n=1 
 
Per protocol analysis (n=136) 
♦ intention to treat analysis (n=151) 
 
Allocation	  
Analysis	  
Follow-­‐Up	  
Randomized (n=329) 
Enrollment	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Table 1  Baseline Characteristics -  mean (SD) or % 567 
 568 
 Rituximab-first 
n = 144 
Anti-TNF-first 
n = 151 
Age (years) 
 
57 (10) 57 (10) 
Gender - % female 
 
72% 72% 
Disease Duration (months) 
 
8.0 (7.4) 6.7 (7.1) 
DAS28-ESR 
 
6.2 (0.9) 6.2 (1.1) 
28 Tender Joint Count 
 
17 (7) 16 (7) 
28 Swollen Joint Count 
 
9 (5) 9 (5) 
Patient Global Health VAS (0-100) 
 
67 (17) 66 (19) 
Pain VAS  (0-100) 
 
62 (18) 63 (22) 
Physician Global VAS (0-100) 
 
63 (17) 62 (19) 
CRP (mg/l) 
 
19 (24) 21 (22) 
ESR (mm/h) 
 
32 (24) 37 (28) 
HAQ (0-3) 
 
1.7 (0.6) 1.8 (0.7) 
EQ5D Health Utility Score 
 
0.34 (0.32) 0.30 (0.33) 
EQ5D VAS Score  (0-100) 
 
48 (22) 43 (23) 
HADS Anxiety >11  
 
29% 29% 
HADS Depression > 11  
 
22% 23% 
Methotrexate Intolerance  
 
26% 25% 
Number of Concomitant DMARD*  
 
1.0 (1.0-2.0) 1.0 (0-2.0) 
* median (IQR)569 
 15 
Figure 2 Non-Inferiority Plot 570 
 571 
 572 
 573 
 574 
 575 
 576 
577 
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  578 
Table 2 Percentage of patients fulfilling response criteria after 6 and 12 months follow-up. Intention-to-579 
treat population 580 
 581 
 Rituximab-first Anti-TNF-first Odds Ratio (95CI) 
DAS28 Remission  
                                                      
6 months 
 
12 months 
 
14% 
 
23% 
 
16% 
 
21% 
 
 
0.9 (0.4, 1.8) 
 
1.1 (0.6, 2.1) 
 
Good response  
 
6 months 
 
12 months 
 
 
29% 
 
43% 
 
 
29% 
 
40% 
 
 
        
1.0 (0.6, 1.8) 
 
1.1 (0.7, 1.9) 
Moderate response  
 
6 months 
 
12 months 
 
 
83% 
 
87% 
 
 
76% 
 
82% 
 
 
1.5 (0.8, 2.8) 
 
1.5 (0.7, 2.9) 
 
No response 
6 months 
 
12 months 
 
17% 
 
13% 
 
24% 
 
18% 
 
0.7 (0.4, 1.2) 
 
0.7 (0.3, 1.3) 
 
ACR20 response 
 
6 months 
 
12 months 
 
 
62% 
 
66% 
 
 
66% 
 
71% 
 
 
0.8 (0.5, 1.4) 
 
0.8 (0.5, 1.4) 
 
ACR50 response 
 
6 months 
 
12 months 
 
 
37% 
 
49% 
 
 
41% 
 
45% 
 
 
0.9 (0.5, 1.4) 
 
1.2 (0.7, 1.9) 
 
ACR70 response 
 
6 months 
 
12 months 
 
 
15% 
 
23% 
 
 
17% 
 
26% 
 
 
0.9 (0.5, 1.7) 
 
0.8 (0.5, 1.5) 
 
 582 
Definitions: DAS remission = DAS28-ESR<2.6; Good response = DAS28-ESR<3.2, with 583 
improvement from baseline >1.2; Moderate response = DAS28-ESR = 3.2-5.1 and improvement 584 
from baseline 0.6-1.2 or DAS28-ESR>5.1 and improvement from baseline >1.2; No response = 585 
DAS2828-ESR <5.1 and improvement from baseline <0.6 or DAS28-ESR >5.1 and improvement 586 
from baseline <1.2 587 
588 
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Table 3 Mean (SD) change from baseline in functional ability, mood and health-related quality of life 589 
outcomes 590 
 591 
 Rituximab-first Anti-TNF-first 
 
P* 
HAQ 
6 months 
 
12 months 
 
-0.44 (0.6) 
 
-0.49 (0.6) 
 
 
-0.31 (0.6) 
 
-0.38 (0.5) 
 
 
0.039** 
EQ5D Health Utility Score 
6 months 
 
12 months 
 
0.2 (0.4) 
 
0.2 (0.4) 
 
0.3 (0.4) 
 
0.3 (0.3) 
 
 
 
0.90 
EQ5D VAS 
6 months 
 
12 months 
 
17 (30) 
 
14 (34) 
 
20 (28) 
 
21 (32) 
 
 
0.48 
 
 
HAD depression 
6 months 
 
12 months 
 
-2.0 (3.4) 
 
-2.1 (3.7) 
 
-2.0 (3.4) 
 
-2.3 (3.4) 
 
 
 
0.60 
HAD anxiety 
6 months 
 
12 months 
 
-1.7 (3.5) 
 
-2.0 (3.4) 
 
-1.5 (2.9) 
 
-1.9 (3.2) 
 
 
 
0.73 
HAD – Hospital Anxiety & Depression; HAQ – Health Assessment Questionnaire 592 
 593 
* Treatment effect over time estimated from linear mixed effect model for rituximab-first vs TNFi-first adjusted for 594 
baseline variable and DAS28-ESR 595 
** Estimated difference (95% CI) = -0.121 (-0.236, -0.006) 596 
 597 
 598 
 599 
 600 
 601 
602 
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Table 4 Healthcare related costs and QALYs over 12 months 603 
 604 
 TNFi-first Rituximab-first  
Medicines, infusions, clinics £10,356 £8,391 p<0.001* 
Primary care £370 £366 p=0.92 
Blood tests, Xray £163 £141 p=0.51 
Total £11,523 £9,405 p<0.001* 
    
Bootstrap estimated mean cost difference (95% CI) = £1,999 (£2,755, £1440) 
  
Quality-Adjusted Life Years (1-EQ-5D AUC) 
QALYs 0.481 0.454 p=0.25 
    
Bootstrap estimated mean QALY difference (95% CI) = 0.028 (-0.041, 0.094) 
 605 
* Wilcoxon 606 
 607 
  608 
 19 
Research in Context 609 
 610 
Evidence before this study 611 
 612 
Biologic disease modifying anti-rheumatic drugs (DMARDs) are used in the treatment of 613 
moderate to severe rheumatoid arthritis (RA) following an insufficient response to 614 
conventional DMARDs. A Pubmed search was carried out on 1st February, 2016 using 615 
the search terms ‘rheumatoid’, rituximab’, ‘adalimumab’, ’etanercept’ and ‘randomised 616 
controlled trial’. There have been several placebo controlled RCTs that have 617 
established the efficacy and safety of these biologic DMARDs; indirect comparisons of 618 
short term efficacy, effectiveness and drug continuation rates have suggested similar 619 
outcomes with rituximab and TNFi therapy, but no head to head comparisons have 620 
been undertaken. 621 
 622 
Added value of this study 623 
 624 
The ORBIT study is the first head to head study that directly compares the efficacy, 625 
safety and cost effectiveness of two strategies of care, and shows that a rituximab-first 626 
treatment strategy is non-inferior to a TNFi-first strategy. Very similar effects on disease 627 
activity, physical function, mood and health-related quality of life were observed. Fewer 628 
patients needed to switch from rituximab to TNFi therapy than vice versa, and there 629 
were no significant differences in the incidence of serious adverse events. Using 630 
rituximab-first was associated with significantly lower health related costs using UK 631 
2015 prices 632 
 633 
Implications of the available evidence 634 
The relative cost-effectiveness of rituximab-first or TNFi-first treatment was dominated 635 
by drug acquisition and administration costs, which are context dependent - the price of 636 
biologic drugs varies according to local procurement agreements, and these are likely to 637 
be substantially affected by the advent of biosimilars that are cheaper than the 638 
originator drugs. This study suggests the cheapest drug is likely to represent the most 639 
cost effective option. However, the study has a 12 month horizon, and RA is a condition 640 
that may affect people over several decades. Consequently, the long term 641 
consequences of any differences in disease progression, effect on life expectance 642 
and/or drug discontinuation rates need to be evaluated. 643 
